Comparing Tevogen Bio (NASDAQ:TVGN) and CytoMed Therapeutics (NASDAQ:GDTC)

Tevogen Bio (NASDAQ:TVGN) and CytoMed Therapeutics (NASDAQ:GDTC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Volatility and Risk

Tevogen Bio has a beta of -0.76, meaning that its share price is 176% less volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Tevogen Bio and CytoMed Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1	1	0	0	1.50
CytoMed Therapeutics	1	0	0	0	1.00

Tevogen Bio presently has a consensus target price of $100.00, suggesting a potential upside of 1,815.71%. Given Tevogen Bio’s stronger consensus rating and higher possible upside, research analysts clearly believe Tevogen Bio is more favorable than CytoMed Therapeutics.

Profitability

This table compares Tevogen Bio and CytoMed Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-761.89%
CytoMed Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares Tevogen Bio and CytoMed Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$13.73 million	($9.50)	-0.55
CytoMed Therapeutics	$50,000.00	N/A	-$1.84 million	N/A	N/A

CytoMed Therapeutics has higher revenue and earnings than Tevogen Bio.

Institutional and Insider Ownership

0.0% of CytoMed Therapeutics shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CytoMed Therapeutics beats Tevogen Bio on 5 of the 8 factors compared between the two stocks.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.